potential €6.45-billion offer significantly undervalued the Spanish drugmaker’s prospects and long-term potential.
Grifols said its board would meet later on Tuesday to consider the potential offer, but that, given the valuation, it would not be in a position to recommend that shareholders accept it.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer: